Acadia Pharmaceuticals Inc. (ACAD) News

Latest headlines that mention ACAD, newest first · each headline opens the original publisher

ACAD quote

Last price: $19.68
Day change: -3.13%
Next earnings: 2026-11-04

Quote & chart Expected move Insider trading IV rank history

ACAD headlines

last 30 days

Investing.com 17d ago

RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments

General T3ACAD

Investing.com 17d ago

Why is ACADIA Pharmaceuticals stock climbing today?

General T3ACAD

Investing.com 25d ago

Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright

General T3ACAD

Seeking Alpha 27d ago

Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results

General T2ACAD

Investing.com 28d ago

Needham cuts Acadia Pharmaceuticals stock price target on trial results

General T3ACAD

Seeking Alpha News 28d ago

ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript

General T2ACAD

Investing.com 28d ago

Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss

General T3ACAD GS

Seeking Alpha News 28d ago

ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis - Slideshow

General T2ACAD

Investing.com 28d ago

TD Cowen reiterates Acadia Pharmaceuticals stock rating on trial data

General T3ACAD

Investing.com 28d ago

BMO cuts Acadia Pharmaceuticals stock price target on trial miss

General T3ACAD

Seeking Alpha News 29d ago

Acadia Pharmaceuticals: Remlifanserin Is In Trouble

General T2ACAD

Investing.com 29d ago

Why is ACADIA Pharmaceuticals stock sliding today?

General T3ACAD

Also mentioned with ACAD

30d

GS1

Headlines that tag both tickers

ACAD news alerts

Get an alert by email or push when a new headline mentions ACAD.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.